GLP-1 Results, Honestly: What the Timeline Really Looks Like

The photo skips the part you're living in

The before-and-after image is a lie of omission. Not the numbers — the numbers are often real — but the timeline. Two photos separated by a caption erase the fourteen months in between: the first weeks when almost nothing moves, the middle stretch when the scale finally slopes, the plateau that arrives and feels like failure, and the maintenance that is supposed to be the point. If you are three weeks in and down four pounds, wondering whether you are the one person the drug does not work for, the problem is not your body. It is that no one showed you the actual curve.

So here is the curve, drawn from the trials that measured it week by week rather than end to end.

Weeks 1 to 4: the drug is not "not working"

The first month is the lowest dose — deliberately. GLP-1s are titrated upward slowly, starting well below the therapeutic dose, precisely to blunt the nausea that comes with dose increases. That means the first weeks are as much about your gut adjusting as about weight coming off. Some women lose a few pounds early, largely water and appetite; some lose almost nothing. Both are normal. In the pivotal trials the meaningful weight loss accrued over months, not weeks, because the dose itself took months to climb. Judging the drug at week three is judging a book by its title page. If the early nausea is the hard part, our first-timer's guide to starting a GLP-1 covers what actually helps.

Months 2 to 6: the slope you were promised

This is where the trajectory earns the headlines. In STEP 1, adults on semaglutide lost about 15% of their body weight on average over 68 weeks, and the weight came off as a steady slope through most of that first year — not a cliff in month one¹. In SURMOUNT-1, tirzepatide reached roughly 20% average weight loss over 72 weeks at the top dose, on the same kind of gradual curve². When the two drugs were finally put head-to-head in SURMOUNT-5, tirzepatide averaged −20.2% and semaglutide −13.7% over 72 weeks³ — different destinations, same shape of journey: a long, mostly steady descent measured in seasons, not weeks.

The honest footnote every average hides: these are group means. Some women in these very trials lost far more; some far less. The trajectory is a reliable shape, not a personal guarantee, and where your own line lands depends on your body, your dose, and whether you can stay on long enough to reach the therapeutic range.

Months 6 to 12+: meet the plateau

Somewhere in the second half of the first year, most people's weight loss slows and then flattens. In the trials the curve bends toward a plateau as the body settles at a new set point — in STEP 1, weight loss largely leveled in the final months of the 68-week study¹. This is the moment that breaks the most people, because it feels like the drug stopped working. It didn't. A plateau after months of loss is the expected biology of the curve, not evidence of failure — the same shape appears in trial after trial. It is a checkpoint to discuss dose and habits with your clinician, not a verdict.

The part the photos never show: after

Here is the fact that should reframe the whole timeline. These drugs are studied as ongoing treatments, not courses you complete. When semaglutide was stopped and swapped for placebo in STEP 4, participants regained much of the weight they had lost⁴. Continuing tirzepatide in SURMOUNT-4 held the reduction, whereas stopping gave much of it back⁵. The "after" photo, in other words, is not an endpoint — it is a weigh-station, and staying there is its own phase with its own plan. We treat that stretch honestly in coming off a GLP-1 and the rebound question.

For a mother, this changes which question matters. Not "how fast will the weight come off" but "can I sustain this — the cost, the routine, the clinical support — for as long as the biology needs?" The cost curve, in particular, climbs as the dose does; we map it in the true cost as the dose climbs.

What a realistic year actually looks like

• Weeks 1–4: low dose, gut adjusting, little scale movement. Normal.
• Months 2–6: the steady slope; most of the visible change lives here¹².
• Months 6–12: loss slows toward a plateau at a new set point¹.
• Beyond: maintenance is an active phase; stopping without a plan invites regain⁴⁵.

The women who are happiest a year in are the ones who set their expectations to this curve instead of the two-photo version — and who chose a program that stays with them across all of it. That continuity is what our Editors' Rating methodology rewards, and why a flat-priced, clinician-led program like CoreAge Rx leads our board of GLP-1 programs for moms: the value is not the fast start, it is who is still there at month eleven. This essay is educational only and is not medical advice; your own timeline belongs to you and your clinician.